Showing 1-5 of 8 :
Artificial Intelligence: Friend or Foe?

Dermatology Times October 3, 2023 Read the full article >> Artificial intelligence (AI) has been a buzzword in health care for some time, but do clinicians, especially in dermatology, view it as friend or foe? Applications and use of AI in dermatology are comparatively new and have focused primarily on the relatively narrow application of[…]

RAPID3 Scores May Help Determine the Impact of DMARD Therapy on PsA Severity

Dermatology Times Mar 19, 2023 Kaitlyn Bader Read the Full Article >>   A poster presentation from AAD 2023 explored RAPID3 scores to evaluate patient-reported outcomes in routine clinical practice therapy decisions regarding PsA. There is a lack of evidence investigating the impact of patient-reported outcomes (PROs) monitoring in routine clinical practice, according to a[…]

Using Real-World Data for Patients with Multiple Sclerosis: A New Machine Learning Model for the Expanded Disability Status Scale (EDSS)

HealthEconomics.com – A Scientist.com Company Publish Date: August 26th, 2022   Multiple sclerosis (MS) is a chronic illness in which the body’s immune system attacks myelin, the substance that surrounds and protects the nerve fibers of the central nervous system. The result is a disabling disease that causes damage to the brain and spinal cord[…]

Dell Medical School helps develop artificial intelligence tool for knee surgery

April 2, 2021 – Austin American-Statesman Read the Full Article >> If you had osteoarthritis in your knee, how would you know when it’s the right time to have knee replacement surgery? Dell Medical School at the University of Texas helped patients at UT Health Austin’s Musculoskeletal Institute answer that question by studying a new artificial intelligence tool[…]

How can AI and RWD work together to improve understanding of chronic diseases? Q&A with Kathryn Starzyk, Head of RWE at OM1

August 13, 2020- Aetion In a recent interview, Kathryn Starzyk, epidemiologist and Head of Real-World Evidence (RWE) at OM1, shared what makes OM1’s data unique, and how she and her team partner with biopharma and health systems to generate RWE that helps researchers better understand patient journeys in disease areas including rheumatology and immunology. Read on[…]